F3 and hemophilia A: ADA development with Mim8 isbeing assessed.109 For antibodies targeting tissue factor pathway inhibitors, withconcizumab, for instance, 25% of patients in the explorer4 (recruitingpatients with hemophilia A or B and inhibitors)/explorer5 (recruitingpatients with severe hemophilia A without inhibitors) trials developed ADAsduring the main and extension phases, with no apparent clinical effect, withthe exception of one patient for whom the clinical impact was inconclusive.110